Moxifloxacin Olikla (Moxifloxacin Hydrochloride)

Moxifloxacin Hydrochloride, the active ingredient in Moxifloxacin Olikla, is a fluoroquinolone antibiotic presented as an ocular formulation for eye use. It treats bacterial infections of the eye, such as conjunctivitis and keratitis, in adult patients and is indicated for topical management of ocular bacterial infections via direct instillation into the conjunctival sac.

GNH USA supplies Moxifloxacin Olikla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory documentation and logistics support for global healthcare providers.

Moxifloxacin Olikla is a fluoroquinolone antibiotic used to treat bacterial infections of the eye. - Bacterial conjunctivitis: reduces bacterial load and accelerates resolution of redness and discharge. - Bacterial keratitis: eradicates causative organisms and promotes corneal healing. - Other ocular bacterial infections: controls infection in conditions such as blepharitis and postoperative ocular inflammation.

Topical ocular administration of Moxifloxacin Olikla may be associated with local and systemic adverse reactions.

Common Side Effects: - Eye irritation: transient burning or stinging sensation after instillation. - Redness: mild conjunctival hyperemia. - Foreign body sensation: feeling of grit in the eye. - Blurred vision: temporary decrease in visual clarity. - Tearing: increased lacrimation. - Eyelid edema: mild swelling of the eyelid margin.

Serious or Rare Side Effects: - Allergic reaction: swelling, itching, or rash around the eye. - Corneal ulceration: worsening of corneal integrity. - Severe eye pain: intense discomfort indicating possible complications. - Vision loss: sudden decrease in visual acuity. - Stevens‑Johnson syndrome: rare systemic hypersensitivity affecting skin and mucosa.

Before prescribing Moxifloxacin Olikla, clinicians should consider several precautionary measures to ensure safe use. - Allergy assessment: confirm no known hypersensitivity to fluoroquinolones or other ophthalmic antibiotics. - Concomitant infection: avoid use if viral or fungal eye infection is suspected. - Corneal health: monitor patients with pre‑existing corneal epithelial defects closely. - Contact lens wear: advise removal of lenses during treatment and until therapy is completed. - Systemic absorption: use the minimal effective dose to limit systemic exposure. - Store at room temperature: keep in the original container, protect from light and moisture.

Moxifloxacin Olikla can interact with other ophthalmic or systemic agents, influencing efficacy or safety.

Major Interactions (Avoid): - Systemic fluoroquinolone therapy: additive toxicity risk, avoid concurrent use. - Topical corticosteroids: may mask infection signs and reduce antibacterial effectiveness.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory eye drops: may increase irritation. - Preservative‑containing contact lens solutions: potential for chemical incompatibility. - Topical anesthetic drops: may enhance corneal toxicity when combined. - Anticholinergic eye drops: possible reduced drug penetration.